ChinaDrugStatus

Ivosidenib

艾伏尼布
Brand: Tibsovo / 拓舒沃·Oncology / Hematology·Last verified 2026-11-20

IDH1 inhibitor whose 2026 NRDL payment scope expands beyond relapsed/refractory AML to cover first-line IDH1-mutated AML combined with azacitidine.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字HJ20220002
Initial Approval Date
Jan 30, 2022
Notice Published
Feb 9, 2022
MAH
Servier Pharmaceuticals LLC (施维雅药厂有限责任公司)
Approved Scope
Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine.

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #298 · Class B
Agreement Period
2027-01-01 to 2027-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy.
限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

2025 vs 2026 NRDL Payment Scope Comparison

2025 NRDL · #258NHSA · PDF p.164

Restricted to adults with relapsed or refractory AML with a susceptible IDH1 mutation.

限诊断为携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者。

2026 NRDL · #298NHSA · PDF p.149

Expanded to 2 indications: (1) Adult r/r IDH1-mutated AML; (2) First-line newly diagnosed IDH1-mutated AML in combination with azacitidine for patients aged ≥75 or ineligible for intensive induction chemotherapy.

限:1.携带易感异柠檬酸脱氢酶-1(IDH1)突变的复发性或难治性急性髓系白血病(AML)成人患者;2.联合阿扎胞苷用于携带易感异柠檬酸脱氢酶-1(IDH1)突变,因合并症无法使用强诱导化疗或者年龄≥75岁的新诊断急性髓系白血病(AML)患者。

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字HJ20220002
Tablet (片剂)
250mg
Initial Approval

Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine.

首发获批用于携带易感IDH1突变的复发或难治性急性髓系白血病(AML)成人患者;后续扩展至联合阿扎胞苷一线治疗新诊断IDH1突变AML。

Approved: 2022-01-30
Published: 2022-02-09
Servier Pharmaceuticals LLC

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Payment Scope Updated

    Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298).

    Chinese original: 支付范围新增联用阿扎胞苷一线治疗≥75岁或不耐受强诱导化疗的新诊断IDH1突变AML患者(原2025版仅限复发/难治AML)。

    NHSA · PDF p.149Verified 2026-11-20
  2. (2022-01-30)NMPA Approval· Notice published: Feb 9, 2022

    NMPA Initial Marketing Approval (国药准字HJ20220002 · 250mg)

    Initial approval for adult relapsed or refractory AML with a susceptible IDH1 mutation; later expanded to first-line IDH1-mutated AML in combination with azacitidine.

    Chinese original: 首发获批用于携带易感IDH1突变的复发或难治性急性髓系白血病(AML)成人患者;后续扩展至联合阿扎胞苷一线治疗新诊断IDH1突变AML。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

艾伏尼布片dosage name(NHSA)
Tibsovobrand en(WHO)
拓舒沃brand zh(NMPA)

Primary Sources for This Record